Premium
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
Author(s) -
Booth Stephen,
Willan John,
Wong Henna,
Khan Dalia,
Farnell Rachel,
Hunter Alicia,
Eyre Toby,
Katz Harley,
Dungarwalla Moez,
Chen Lucia,
Browning Joe,
Polzella Paolo,
Gray Nicola,
Neelakantan Pratap,
Dhillon Elissa K.,
Dutton David,
Sternberg Alex,
Prideaux Steven,
Collins Graham P.,
Peniket Andy
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13469
Subject(s) - medicine , case fatality rate , malignancy , mortality rate , hematological malignancy , population , coronavirus , pediatrics , covid-19 , epidemiology , disease , infectious disease (medical specialty) , environmental health
Objectives We sought to characterise the outcomes of patients with haematological malignancy and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in hospital in our regional network of 7 hospitals. Methods Consecutive hospitalised patients with haematological malignancy and SARS‐CoV‐2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive. Results 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS‐CoV‐2 infection was associated with a significantly higher pCFR of 70%, compared with 28% in those not on active treatment ( P = .0013, 2 proportions z test). Conclusions Mortality rates in patients with haematological malignancy and SARS‐CoV‐2 infection in hospital are high supporting measures to minimise the risk of infection in this population.